SC79,一个特异的、能透过血脑屏障的Akt激动剂,可激活胞质中Akt,并抑制 Akt 膜转位。SC79 特异性结合Akt 的PH 结构域。
生物活性 | SC79, a unique specific and BBB permeableAktactivator, activatesAktin the cytosol and inhibitsAktmembrane translocation. SC79 specifically binds to the PH domain ofAkt[1][2][3]. |
体外研究 (In Vitro) | SC79 augmentes Akt phosphorylation at both the Thr308 and S473 sites[1]. SC79 (10.96 μM) induces cytosolic phosphorylation of Akt. SC79 enhances IGF1-induced Akt phosphorylation in both serum-starved cells and cells grown in serum-rich medium[1]. SC79 reduces neuronal excitotoxicity and prevents stroke-induced neuronal death. SC79 suppresses PHAKTM-GFP plasma membrane translocation[1]. SC79 restores proliferation of BRAT1 knockdown cells, and reduces the production of superoxide in mitochondria of MitoSox positive cells[2]. SC79 upregulates FLIPL/S expression and consequently suppresses caspase-8 activation[5].
Western Blot Analysis[1] Cell Line: | HeLa cells. | Concentration: | 4 μg/mL (10.96 μM). | Incubation Time: | 30 min. | Result: | Induced cytosolic phosphorylation of Akt. |
|
体内研究 (In Vivo) | SC79 treatment, even at much high dose (0.4 mg/g of body weight), does not induce any detectable changes in body weight, survival rate, appearance, and behavior in mice[1]. SC79 (10 mg/kg, i.p.) Protects C57BL/6 mice from fas-induced fulminant hepatic failure[4]. SC79 protects hepatocytes from TNFα-mediated apoptosis and mice from Gal/LPS-induced liver injury and damage[5].
Animal Model: | Male, age-matched (6- to 8-weekeold) C57BL/6 or BALB/c mice weighing 16 to 18 g[4]. | Dosage: | 10 mg/kg. | Administration: | Intraperitoneally at 0.5 hour before the i.p. administration of an agonistic anti-Fas Jo2 antibody at a lethal dose of 0.5 and 0.4 mg/kg for C57BL/6 and BALB/c mice, respectively. | Result: | Treatment of mice with 10 mg/kg of SC79 at 0.5 hour before Jo2 injection increased mouse survival at 12 hours after Jo2 injection from 0% to 35%, and no additional mortality was observed to the end of the 2-month observation period. |
Animal Model: | Male, age-matched (6 to 8 weeks old) C57BL/6 mice weighing 16-18 g[5]. | Dosage: | 10 mg/kg. | Administration: | Intraperitoneally at 0.5 h before i.p. administration of 400 mg/kg of D-galactosamine (D-Gal) and 60 μg/kg of lipopolysaccharide (LPS) for C57BL/6 mice. | Result: | Gal/LPS challenge there was more bleeding on the liver of the vehicle control-treated mice as compared to that of SC79-treated mice. A single dose of SC79 significantly reduced Gal/LPS-mediated liver damage but not an infiltration of inflammatory cells in liver sections.
|
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years |
*该产品在溶液状态不稳定,建议您现用现配,即刻使用。 |
溶解性数据 | In Vitro: DMSO : 100 mg/mL(274.14 mM;Need ultrasonic) 配制储备液 1 mM | 2.7414 mL | 13.7069 mL | 27.4138 mL | 5 mM | 0.5483 mL | 2.7414 mL | 5.4828 mL | 10 mM | 0.2741 mL | 1.3707 mL | 2.7414 mL |
*请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 5% DMSO 40%PEG300 5%Tween-80 50% saline Solubility: 5 mg/mL (13.71 mM); Suspended solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.85 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.85 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.85 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.85 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|